持股 5%以上的股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"本公司"或"公司"）就持股 5%以上 股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）拟减持公司股份的意 向预披露了《关于持股 5%以上股东股份减持计划期限届满及未来减持计划预披露的 公告》（公告编号：2023-028），和丰投资拟通过集中竞价交易方式减持公司股份 合计不超过公司总股本比例 2.00%。 近日，公司收到股东和丰投资提交的《关于股份减持计划期限届满的告知函》， 本次减持股份计划期限届满。在本次减持计划期间，和丰投资通过深圳证券交易所 以集中竞价方式共减持公司股份 670,000 股（占公司总股本比例 0.4188%）。 根据《上市公司股东、董监高减持股份的若干规定》（证监会公告[2017]9 号） 及《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》 的相关规定，现将和丰投资股份减持计划实施情况公告如下： 证 ...

Financial Performance - The company's revenue for Q3 2023 was ¥67,075,377.49, a decrease of 27.08% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥20,160,102.38, down 29.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥19,593,617.82, reflecting a 31.98% decline compared to the previous year[5] - Total operating revenue for the third quarter was CNY 216.11 million, a decrease of 17.7% compared to CNY 262.45 million in the same period last year[19] - Net profit for the third quarter was CNY 58.70 million, representing a decline of 34.3% from CNY 89.40 million in the previous year[20] - Earnings per share for the third quarter were CNY 0.37, down from CNY 0.56 in the same quarter last year[20] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥919,269,079.44, a decrease of 4.02% from the end of the previous year[5] - The company's total current assets as of September 30, 2023, amount to ¥777,543,459.59, a decrease from ¥812,262,950.53 at the beginning of the year[16] - The total assets of the company as of September 30, 2023, are ¥919,269,079.44, down from ¥957,759,191.66 at the start of the year[16] - The total liabilities of the company as of September 30, 2023, are ¥71,211,819.77, a decrease from ¥88,367,651.86 at the beginning of the year[16] - Total liabilities amounted to CNY 81.25 million, a decrease from CNY 98.86 million in the previous year[20] Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,748,650.66, a significant decrease of 55.36% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of CNY 41.75 million, significantly lower than CNY 93.52 million in the previous year[22] - The net cash flow from investing activities increased by 143.37% to ¥20,486,792.61, mainly due to increased redemption of financial products[9] - The company reported a net cash flow from investment activities of CNY 20.49 million, an increase from CNY 8.42 million year-over-year[22] - Cash flow from financing activities decreased to -80 million from -96 million year-over-year[23] - The net increase in cash and cash equivalents was -17.76 million compared to an increase of 5.94 million in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,152[10] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[10] - The number of restricted shares held by Wang Yuejun remains at 45,900,000, with no shares released during the period[13] - The company has no preferred shareholders as indicated in the report[12] Inventory and Receivables - Accounts receivable decreased by 30.82% to ¥16,467,773.43 due to reduced shipments compared to the previous year[8] - Inventory increased by 29.93% to ¥59,957,414.26, attributed to decreased shipments at the end of the reporting period[8] - The inventory level has increased to ¥59,957,414.26 from ¥46,146,719.95 at the beginning of the year[15] Financial Expenses and Equity - The company reported a 54.12% increase in financial expenses, totaling -¥13,066,151.75, primarily due to increased bank deposit interest[8] - The total equity attributable to shareholders was CNY 838.02 million, down from CNY 858.89 million year-over-year[20] - Deferred income tax liabilities increased to CNY 502.06 million from CNY 426.23 million in the previous year[20] Strategic Developments - The company has not reported any new strategies or significant market expansions in the current quarter[14]

证券代码：300519 独立董事发表的独立意见 浙江新光药业股份有限公司独立董事关于 第四届董事会第十二次会议相关事项发表的独立意见 浙江新光药业股份有限公司（以下简称"公司"）于 2023 年 10 月 23 日召 开第四届董事会第十二次会议，根据相关法律、法规、规范性文件及公司章程的 规定， 我们作为公司独立董事，基于独立、客观、公正的立场，对会议审议的 相关事项发表独立意见如下： 证券代码：300519 独立董事发表的独立意见 （本页无正文，为浙江新光药业股份有限公司独立董事关于第四届董事会第十二 次会议相关事项发表的独立意见签字页） 一、关于 2023 年第三季度报告全文的独立意见 经核查，我们认为：董事会编制和审核《公司 2023 年第三季度报告全文》 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、关于公司 2023 年第三季度关联交易事项的独立意见 经核查，我们认为：报告期内，公司未发生重大关联交易行为。 三、关于控股股东及其他关联方资金占用和对外担保事项的独立意见 经核查，我们认为：报告期内，公司控 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥149,038,556.10, a decrease of 12.57% compared to ¥170,464,124.83 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was ¥38,539,667.00, down 36.62% from ¥60,804,863.66 in the previous year[19]. - Basic earnings per share for the first half of 2023 were ¥0.24, a decline of 36.84% from ¥0.38 in the previous year[19]. - Operating profit decreased by 36.55% to ¥45,334,468.29 from ¥71,450,894.51 year-on-year, primarily due to reduced revenue and increased raw material costs[35]. - The total comprehensive income decreased by 36.06% to ¥38,874,107.27 from ¥60,801,527.94 in the same period last year[36]. - The company's net profit for the first half of 2023 is CNY 38,539,667, a decrease of 36.5% compared to CNY 60,804,863 in the same period of 2022[131]. - The total revenue for the first half of 2023 is CNY 148,490,166.82, down from CNY 170,464,124.83 in the first half of 2022, representing a decline of 12.9%[133]. - The company's financial expenses showed a significant improvement, with a net financial expense of CNY -2,715,615.94 compared to CNY -7,610,282.85 in the previous year[131]. Cash Flow and Investments - The net cash flow from operating activities decreased by 58.28%, amounting to ¥29,193,593.04 compared to ¥69,982,644.10 in the same period last year[19]. - The company reported a significant increase in cash and cash equivalents net decrease of 340.53%, amounting to -¥75,958,161.24 compared to -¥17,242,412.86 last year[35]. - The company's cash flow from investing activities showed a net outflow of -¥25,151,754.28, a decrease of 386.63% compared to a net inflow of ¥8,774,943.04 last year, primarily due to increased purchases of bank wealth management products[35]. - The total cash outflow for investment activities was CNY 317,302,981.68, which is an increase of 25% from CNY 253,840,022.09 in the first half of 2022[137]. - The company received CNY 260,000,000.00 from other investment activities, an increase of 36.8% compared to CNY 190,000,000.00 in the previous year[138]. Assets and Liabilities - Total assets at the end of the reporting period were ¥895,933,532.48, representing a decrease of 6.46% from ¥957,759,191.66 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 4.79%, totaling ¥817,768,658.50 compared to ¥858,894,551.23 at the end of the previous year[19]. - The total current assets as of June 30, 2023, amount to 755,805,204.11 CNY, a decrease from 812,262,950.53 CNY at the beginning of the year[123]. - Total liabilities decreased from CNY 98,864,640.43 to CNY 78,164,873.98, a reduction of about 20.83%[125]. - Owner's equity decreased from CNY 858,894,551.23 to CNY 817,768,658.50, a decline of approximately 4.79%[125]. Research and Development - Research and development expenses increased by 4.08% to ¥7,673,241.07 from ¥7,372,575.98 year-on-year[35]. - The company has established a provincial-level high-tech research and development center and collaborates with several universities for product innovation, holding 11 core independent intellectual property rights[31][32]. - The company plans to establish a wholly-owned subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co., Ltd., in Hangzhou to enhance R&D efficiency and attract high-end technical talent[47]. - The company has committed to increasing R&D investment in response to significant changes in the pharmaceutical industry policies, focusing on the creation of new traditional Chinese medicines[47]. Market and Product Strategy - The company primarily engages in the research, production, and sales of traditional Chinese medicine, chemical drugs, and health foods, focusing on cardiovascular diseases and other medical areas[27]. - Key products include Huangqi Shengmai Drink, Shenjindan Capsules, and American Ginseng Oral Liquid, with Huangqi Shengmai Drink being particularly noted for its efficacy in treating coronary heart disease[27][30]. - The company has developed sugar-free versions of its products to cater to the growing market of diabetes patients, indicating a proactive approach to market demands[30]. - The company is expanding its market presence in Asia, targeting a 5% increase in market share by the end of the year[53]. - New product launches are expected to contribute an additional 1 billion in revenue over the next fiscal year[53]. Risk Management - The company faces risks related to industry policy changes, medical insurance policy changes, and fluctuations in raw material prices[3]. - The company emphasizes the importance of risk awareness among investors regarding future plans and forecasts[3]. - The company will actively monitor potential risks and take timely measures to achieve its operational goals for 2023[3]. - The company faces pressures from price reductions due to national healthcare reforms and centralized procurement, impacting future sales strategies[29]. - The company faces risks from fluctuating raw material prices, particularly for key Chinese medicinal herbs[64]. Corporate Governance and Compliance - The company has not engaged in any significant litigation or arbitration matters during the reporting period[88]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[84]. - The company has not issued any non-standard audit reports for the current or previous periods[87]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[112]. - The financial report for the first half of the year has not been audited[121]. Social Responsibility and Sustainability - The company emphasizes its commitment to social responsibility and aims to enhance human life quality while promoting the health industry[80]. - The company plans to invest 5% of its revenue into sustainability initiatives over the next three years[53]. - The company has implemented a complete environmental monitoring plan and has not exceeded pollution discharge standards[78].

编制单位：浙江新光药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名 | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 年 1-6 月占 用累计发生金额 | 2023 年 1-6 月占 用资金的利息 | 2023 年 1-6 月 偿还累计发生 | 2023 年 6 | 月末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 称 | 司的关联关系 | 的会计科目 | 占用资金余额 | （不含利息） | （如有） | 金额 | 占用资金余额 | | 原因 | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 小 计 | | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | | 小 计 | | | | | ...

证券代码：300519 证券简称：新光药业 公告编号：2023-032 浙江新光药业股份有限公司 第四届董事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长王岳钧先生召集，会议通知于 2023 年 8 月 16 日以 专人送达、电子邮件、电话等形式送达全体董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2023 年 8 月 23 日在浙江省嵊州市剡湖街道环城西路 25 号公司三楼会议室召开，采取现场投票和通讯表决相结合的方式进行表决。 3、本次会议应出席董事 9 名，实际出席董事 9 名，其中宋夏云、王虎根、 祝明等三位董事采用通讯方式参加会议并表决。 4、本次会议由董事长王岳钧先生召集及主持，公司监事及高级管理人员列 席了会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等相 关法律法规和公司章程的规定。 二、董事会会议审议情况 表决结果：9 票赞成，0 票反对，0 票弃权。 公司《2023 年半年度报告》全文 ...

浙江新光药业股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发的 深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上〔2022〕 14 号）的规定，将本公司募集资金 2023 年上半年存放与使用情况专项说明如下。 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2016〕1179 号文核准，本公司由主承销商太平 洋证券股份有限公司采用向社会公开发行方式，向社会公众公开发行人民币普通股（A 股） 股票 2,000 万股，发行价为每股人民币 12.20 元，共计募集资金 24,400.00 万元，坐扣承销 和保荐费用 1,700.00 万元后的募集资金为 22,700.00 万元，已由主承销商太平洋证券股份 有限公司于 2016 年 6 月 16 日汇入本公司募集资金监管账户。另减除上网发行费、招股说明 书印刷费、申报会计师费、律师费、评估费等与发 ...

证券代码：300519 独立董事发表的独立意见 浙江新光药业股份有限公司独立董事 关于第四届董事会第十一次会议相关事项的独立意见 浙江新光药业股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日召开 第四届董事会第十一次会议，根据相关法律、法规、规范性文件及公司章程的规 定， 我们作为公司独立董事，基于独立、客观、公正的立场，对会议审议的相 关事项发表独立意见如下： 一、关于公司 2023 年半年度控股股东及其他关联方占用公司资金、公司对 外担保情况、关联交易情况的独立意见 独立董事：____________、 _____________、 _____________ 二、关于《2023 年半年度募集资金存放与使用情况的专项报告》的独立意 见 经对公司 2023 年半年度募集资金存放与使用情况的核查，全体独立董事认 为：本专项报告符合《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》、《深圳证券交易所创业板股票上市规则》、《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》以及公司《募集资 金管理制度》等有关规定，内容真实、准确、完整，不存在虚假记载 ...

证券代码：300519 监事会审核意见 浙江新光药业股份有限公司监事会 关于第四届监事会第十一次会议审议事项的审核意见 根据《公司法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律法 规和浙江新光药业股份有限公司(以下简称"公司")《公司章程》、《监事会议 事规则》等公司制度的有关规定,公司监事会就第四届监事会第十一次会议审议 事项发表如下审核意见： 一、《关于公司 2023 年半年度报告全文及摘要的议案》的审核意见 经审核，监事会认为董事会编制和审核《公司 2023 年半年度报告》及 《2023 年半年度报告摘要》的程序符合法律、法规和中国证监会的有关规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 二、《关于 2023 年半年度募集资金存放与使用情况的专项报告的议案》的 审核意见 公司根据相关法律法规、规范性文件的规定签署募集资金专户存储监管协 议，对募集资金采取专户存储管理。公司制作的《2023 年半年度募集资金存放与 使用的专项报告》，及时、真实、准确、完整地披露了公司 ...

证券代码：300519 证券简称：新光药业 公告编号：2023-033 浙江新光药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席孙筑平召集，会议通知于 2023 年 8 月 16 日 以专人送达、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2023 年 8 月 23 日在公司三楼会议室召开，采取现场投 票的方式进行表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席孙筑平先生主持，公司董事会秘书、财务总 监和证券事务代表列席了本次监事会。 会议审议并通过了如下议案： 1、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审核《公司 2023 年半年度报告》及《2023 年半年度报告摘要》的程序符合法律、法规和中国证监会的有关规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 ...